Bacterial packaging strains useful for generation and production of recombinant double-stranded RNA nucleocapsids and uses thereof
Bacterial packaging strains useful for generating recombinant double-stranded RNA nucleocapsids (rdsRNs) are provided. The packaging strains are useful for the production of RNA encoding vaccine antigens, bioactive proteins, immunoregulatory proteins, antisense RNAs, and catalytic RNAs in eukaryotic cells or tissues. Recombinant ssRNA is introduced into the strains and packaged to form rdsRNs de novo.
1. A recombinant double-stranded RNA nucleocapsid (rdsRN), comprising
a) proteins with RNA packaging activity, and
b) RNA sequences comprising at least:
i) RNA encoding a product, and
ii) an RNA of interest operably linked to a eukaryotic translation initiation sequence.
2. The rdsRN of claim 1 , further comprising nucleic acid sequences encoding segment-L of an RNA phage.
3. The rdsRN of claim 1 , wherein said RNA sequences comprise at least a portion of segment-S of an RNA phage or segment-M of an RNA phage, or both.
4. The rdsRN of claim 3 , wherein said portion of segment-S is a segment-S pac sequence, gene 8, or the wild-type segment-S.
5. The rdsRN of claim 3 , wherein said portion of segment-S is a segment-S RNA dependent polymerase recognition sequence.
6. The rdsRN of claim 3 , wherein said portion of segment-M is a segment-M pac sequence.
7. The rdsRN of claim 3 , wherein said portion of segment-M is a segment-M RNA dependent polymerase recognition sequence.
8. The rdsRN of claim 1 , wherein said product complements a selectable phenotypic mutation in a host cell.
9. The rdsRN of claim 8 , wherein said phenotypic mutation is selected from the group consisting of aroA, aroC, and leuD.
10. The rdsRN of claim 8 , wherein said phenotypic mutation is a cell wall synthesis mutation.
11. The rdsRN of claim 10 , wherein said cell wall synthesis mutation is selected from the group consisting of asd and murI.
12. The rdsRN of claim 8 , wherein said phenotypic mutation is a mutation that prevents growth at temperatures above 32° C.
13. The rdsRN of claim 12 , wherein said phenotypic mutation is htrB.
14. The rdsRN of claim 1 , wherein said proteins with RNA packaging activity are derived from a phage selected from the group consisting of Phi-6, Phi-8 and Phi-13.
15. The rdsRN of claim 1 , wherein said RNA of interest encodes a protein selected from the group consisting of a viral antigen, a bacterial antigen, a parasitic antigen, a tumor antigen, a transplant antigen, an autoimmune antigen, an adjuvant and a cytokine.
16. The rdsRN of claim 1 , wherein one or more of said RNA sequences are fluorinated.
17. The rdsRN of claim 10 , wherein said cell wall synthesis mutation is asd.
18. The rdsRN of claim 14 , wherein said proteins with RNA packaging activity are derived from phage Phi-8 and include gene 8 of phage Phi-8.
19. The rdsRN of claim 15 , wherein said protein is a bacterial antigen.
20. The rdsRN of claim 19 , wherein said bacterial antigen is a tuberculosis antigen.
21. The rdsRN of claim 1 , wherein said RNA of interest encodes an apoptosis enhancing protein.
22. The rdsRN of claim 1 , wherein said RNA of interest encodes a tolerance inducing protein, wherein said tolerance inducing protein is Caspase 9.
23. The rdsRN of claim 1 , wherein said RNA sequences comprises nuclease resistant RNA.
24. The rdsRN of claim 23 , wherein said nuclease resistant RNA is fluorinated RNA.
25. The rdsRN of claim 8 , wherein said selectable phenotypic mutation is a non-reverting selectable phenotypic mutation.